Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. (OCUL)
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ocutx.com
Company Research
Source: GlobeNewswire
BEDFORD, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to its newly appointed Executive Director, Payer Access, Thomas J. Cella, and one other newly hired non-executive employee. The awards were made as inducements material to the individual’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of April 7, 2025 and consist of (i) for Mr. Cella, a non-statutory stock option to purchase up to 26,000 shares of Ocular’s common stock and a restricted stock unit award representing the right to receive 8,500 shares of Ocular’s common stock, and (ii) for the other newly hired non-executive employee, a non-statutory stock option to purchase up to 23,500 shares of Ocular’s commo
Show less
Read more
Impact Snapshot
Event Time:
OCUL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUL alerts
High impacting Ocular Therapeutix, Inc. news events
Weekly update
A roundup of the hottest topics
OCUL
News
- Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $21.00 price target on the stock.MarketBeat
- Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $20.00 price target on the stock.MarketBeat
- Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMDGlobeNewswire
- Ocular Therapeutix (OCUL) Valuation After Accelerated AXPAXLI NDA Plan in Wet AMD [Yahoo! Finance]Yahoo! Finance
OCUL
Earnings
- 11/4/25 - Beat
OCUL
Sec Filings
- 12/18/25 - Form 8-K
- 12/8/25 - Form SCHEDULE
- 12/5/25 - Form 8-K
- OCUL's page on the SEC website